ReviewComputational and structural biotechnology journal2019
Structural Biology and Protein Engineering of Thrombolytics.
Review in Computational and structural biotechnology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 73 citations in OpenAlex.
- Rapid screening of staphylokinase protein variants using an unpurified cell-free expression system.FEBS open bio · 2026Article
- Mapping the Mutational Landscape for Streptokinase Binding to Plasminogen.bioRxiv : the preprint server for biology · 2026Article
- Thrombolytic proteins profiling: High-throughput activity, selectivity, and resistance assays.FEBS open bio · 2026Article
- Rather a versatile multi-tool than a sword: an integral role of the plasminogen system in health and disease.Frontiers in immunology · 2026Review
- Epitope mapping strategies for immunogenicity mitigation in streptokinase therapeutics: an in-silico study.Scientific reports · 2025Article
- Streptokinase is dispensable in Streptococcus dysgalactiae subspecies equisimilis infections of human dendritic cells.Scientific reports · 2025Article
- Thrombolysis for acute ischaemic stroke: development and update.Brain communications · 2025Review
- Anti-stroke biologics: from recombinant proteins to stem cells and organoids.Stroke and vascular neurology · 2024Review
- Acute ischemic stroke: research perspective vs. clinical practice.Neurosurgical review · 2024Article
- Glycosylation: mechanisms, biological functions and clinical implications.Signal transduction and targeted therapy · 2024Review
- Therapeutic management of ischemic stroke.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Sonothrombolysis for Ischemic Stroke.Journal of cardiovascular development and disease · 2024Review
- Internal fibrinolysis of fibrin clots is driven by pore expansion.Scientific reports · 2024Article
- Targeted drug delivery to the thrombus by fusing streptokinase with a fibrin-binding peptide (CREKA): anTherapeutic delivery · 2024Article
- The Recent Applications of PLGA-Based Nanostructures for Ischemic Stroke.Pharmaceutics · 2023Review
- Andrographolide-treated bone marrow mesenchymal stem cells-derived conditioned medium protects cardiomyocytes from injury by metabolic remodeling.Molecular biology reports · 2023Article
- Fibrinolysis: an illustrated review.Research and practice in thrombosis and haemostasis · 2023Review
- Immunogenic epitope scanning in bacteriolytic enzymes Pal and Cpl-1 and engineering Pal to escape antibody responses.Frontiers in immunology · 2023Article
- Disseminated Intravascular Coagulation in Varying Age Groups Based on Clinical Conditions.Cureus · 2022Review
- Computer-aided engineering of staphylokinase toward enhanced affinity and selectivity for plasmin.Computational and structural biotechnology journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction and ischemic stroke are the most frequent causes of death or disability worldwide. Due to their ability to dissolve blood clots, the thrombolytics are frequently used for their treatment. Improving the effectiveness of thrombolytics for clinical uses is of great interest. The knowledge of the multiple roles of the endogenous thrombolytics and the fibrinolytic system grows continuously. The effects of thrombolytics on the alteration of the nervous system and the regulation of the cell migration offer promising novel uses for treating neurodegenerative disorders or targeting cancer metastasis. However, secondary activities of thrombolytics may lead to life-threatening side-effects such as intracranial bleeding and neurotoxicity. Here we provide a structural biology perspective on various thrombolytic enzymes and their key properties: (i) effectiveness of clot lysis, (ii) affinity and specificity towards fibrin, (iii) biological half-life, (iv) mechanisms of activation/inhibition, and (v) risks of side effects. This information needs to be carefully considered while establishing protein engineering strategies aiming at the development of novel thrombolytics. Current trends and perspectives are discussed, including the screening for novel enzymes and small molecules, the enhancement of fibrin specificity by protein engineering, the suppression of interactions with native receptors, liposomal encapsulation and targeted release, the application of adjuvants, and the development of improved production systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.